Problems with the use of oxycodone compound in patients with chronic pain.
In a pain management program (200 patients), a group of daily users of oxycodone compound (29 patients) and a subgroup who were taking a "high dose" of oxycodone compound (13 patients) were compared with a group of 171 non-users of oxycodone compound. A significantly lower treatment success rate was observed in the users (P = 0.04) and high-dose users (P = 0.03). A similar trend was seen in preliminary data available in a larger sample (514 patients). Continued study of these findings is necessary. Meanwhile, in patients with chronic pain, there should be cautious use of this compound.
D001241:Aspirin / Q000627:therapeutic use*; D002110:Caffeine / Q000627:therapeutic use*; D002908:Chronic Disease; D003061:Codeine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011431:Dextropropoxyphene / Q000627:therapeutic use; D004338:Drug Combinations / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D008614:Meperidine / Q000627:therapeutic use; D008875:Middle Aged; D010098:Oxycodone / Q000627:therapeutic use*; D010146:Pain / Q000188:drug therapy*; D010423:Pentazocine / Q000627:therapeutic use; D010615:Phenacetin / Q000627:therapeutic use*
D004338:Drug Combinations; D002110:Caffeine; C025153:Aspirin-oxycodone hydrochloride-oxycodone terephthalate combination; D008614:Meperidine; D010098:Oxycodone; D010615:Phenacetin; D001241:Aspirin; D010423:Pentazocine; D011431:Dextropropoxyphene; D003061:Codeine